Related Experiment Video
Updated: Nov 6, 2025
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Nanoparticle conjugation of ginsenoside Rb3 inhibits myocardial fibrosis by regulating PPARα pathway
Background:
Cardiac fibrosis occurs in ischemic and non-ischemic heart failure, hereditary cardiomyopathy, diabetes and aging. Energy metabolism, which serves a crucial function in the course and treatment of cardiovascular diseases, might have therapeutic benefits for myocardial fibrosis. Ginsenoside Rb3 (G-Rb3) is one of the main components of Ginseng and exhibits poor oral bioavailability but still exerts regulate energy metabolism effects in some diseases. Therefore, the study investigated the effect of chitosan (CS) @ sodium tripolyphosphate (TPP) nanoparticles conjugation with ginsenoside Rb3 (NpRb3) on myocardial fibrosis and studied its possible mechanisms. The results showed that NpRb3 directly participates in the remodeling of myocardial energy metabolism and the regulation of perixisome proliferation-activated receptor alpha (PPARα), thereby improving the degree of myocardial fibrosis. The study also verifies the protective effect of NpRb3 on energy metabolism and mitochondrial function by targeting the PPARα pathway. Therefore, the prepared nanodrug carrier may be a potential solution for the delivery of G-Rb3, which is a promising platform for oral treatment of myocardial fibrosis.
Insights
Chitosan-Ginsenoside Rb3 nanoparticles improve cardiac fibrosis by regulating energy metabolism and targeting the PPARα pathway. This nanodrug carrier shows promise for oral treatment of myocardial fibrosis.
Area of Science:
- Cardiovascular Research
- Nanomedicine
- Metabolic Disorders
Background:
- Cardiac fibrosis is a hallmark of various heart conditions, including heart failure and aging.
- Energy metabolism plays a critical role in cardiovascular disease progression and treatment.
- Ginsenoside Rb3 (G-Rb3), a component of Ginseng, has shown potential in regulating energy metabolism despite poor oral bioavailability.
Purpose of the Study:
- To investigate the effects of chitosan (CS) @ sodium tripolyphosphate (TPP) nanoparticles conjugated with ginsenoside Rb3 (NpRb3) on myocardial fibrosis.
- To elucidate the underlying mechanisms, focusing on energy metabolism and the PPARα pathway.
Main Methods:
- Preparation and characterization of NpRb3 nanoparticles.
- Assessment of NpRb3's impact on myocardial fibrosis in relevant models.
- Analysis of energy metabolism, PPARα pathway activation, and mitochondrial function.
Main Results:
- NpRb3 directly remodels myocardial energy metabolism and regulates perixisome proliferation-activated receptor alpha (PPARα).
- NpRb3 administration significantly improves the degree of myocardial fibrosis.
- The study verified the protective effects of NpRb3 on energy metabolism and mitochondrial function via the PPARα pathway.
Conclusions:
- NpRb3 effectively ameliorates myocardial fibrosis by targeting the PPARα pathway and modulating energy metabolism.
- The developed nanodrug carrier offers a potential solution for oral delivery of G-Rb3.
- NpRb3 represents a promising therapeutic platform for treating myocardial fibrosis.
